PMID- 28469143
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20221207
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 May 3
TI  - Impact of platinum/pemetrexed combination versus other platinum-based regimens on 
      adjuvant chemotherapy in resected lung adenocarcinoma.
PG  - 1453
LID - 10.1038/s41598-017-01347-6 [doi]
LID - 1453
AB  - For advanced non-squamous non-small cell lung cancer (NSCLC), although 
      platinum/pemetrexed is known to result in a longer survival compared with other 
      regimens, the outcome in the adjuvant setting is still unknown. In this study, 
      the difference of the disease-free survival (DFS) between lung adenocarcinoma 
      patients treated with platinum/pemetrexed and with other platinum-based doublets 
      was concerned. A total of 389 radically resected lung adenocarcinoma patients 
      received adjuvant chemotherapy with platinum/pemetrexed chemotherapy (Group A, 
      n = 143) or other third generation platinum-based regimens (Group B, n = 246) 
      were analyzed in terms of DFS. Propensity score matching (PSM) allowed generation 
      of best matched pairs for the two categories. DFS was proved to be considerably 
      better in pemetrexed doublets group (P = 0.0079); and platinum/pemetrexed was 
      found to be associated with lower rates of several hematological and 
      non-hematological adverse events (AEs), when compared with gemcitabine containing 
      chemotherapy (leukopenia: RR 0.514, p = 0.001; neutropenia: RR 0.688, p = 0.002), 
      or taxanes-doublets treatment (leukopenia: RR 0.685, p = 0.019; neutropenia: RR 
      0.805, p = 0.032). For patients with radically resected pulmonary adenocarcinoma, 
      adjuvant chemotherapy with platinum/pemetrexed results in a better DFS and a less 
      clinical toxicity in comparison with non-pemetrexed based doublets.
FAU - Zhai, Xiaoyu
AU  - Zhai X
AD  - Department of Medical Oncology, National Cancer Centre/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Zheng, Qiwen
AU  - Zheng Q
AD  - Medical Insurance Office, Peking University Cancer Hospital & Institute, Beijing, 
      China.
FAU - Yang, Lu
AU  - Yang L
AD  - Department of Medical Oncology, National Cancer Centre/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Zhu, Yixiang
AU  - Zhu Y
AD  - Department of Medical Oncology, National Cancer Centre/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Li, Junling
AU  - Li J
AD  - Department of Medical Oncology, National Cancer Centre/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Liu, Yutao
AU  - Liu Y
AD  - Department of Medical Oncology, National Cancer Centre/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China. 13911901165@139.com.
FAU - Wang, Ziping
AU  - Wang Z
AD  - Department of Medical Oncology, National Cancer Centre/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China. wangzp2007@126.com.
AD  - Department of Thoracic Medical Oncology, Peking University School of Oncology, 
      Beijing Cancer Hospital & Institute, Beijing, China. wangzp2007@126.com.
LA  - eng
PT  - Journal Article
DEP - 20170503
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Taxoids)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 49DFR088MY (Platinum)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adenocarcinoma of Lung/*drug therapy/mortality/pathology/surgery
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology/surgery
MH  - Chemotherapy, Adjuvant/*methods
MH  - Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Leukopenia/drug therapy/etiology/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neutropenia/drug therapy/etiology/mortality/pathology
MH  - Pemetrexed/*administration & dosage/adverse effects
MH  - Platinum/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Taxoids/administration & dosage/adverse effects
MH  - Gemcitabine
PMC - PMC5431114
COIS- The authors declare that they have no competing interests.
EDAT- 2017/05/05 06:00
MHDA- 2018/12/12 06:00
PMCR- 2017/05/03
CRDT- 2017/05/05 06:00
PHST- 2017/01/04 00:00 [received]
PHST- 2017/03/27 00:00 [accepted]
PHST- 2017/05/05 06:00 [entrez]
PHST- 2017/05/05 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/05/03 00:00 [pmc-release]
AID - 10.1038/s41598-017-01347-6 [pii]
AID - 1347 [pii]
AID - 10.1038/s41598-017-01347-6 [doi]
PST - epublish
SO  - Sci Rep. 2017 May 3;7(1):1453. doi: 10.1038/s41598-017-01347-6.